Athira Pharma & Prime Medicine Compared in New Analysis

Analysts weigh in on which small-cap biotech stock is the better investment.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

A new analysis from Transcript Daily compares two small-cap biotech companies, Prime Medicine (NASDAQ:PRME) and Athira Pharma (NASDAQ:LONA), to determine which is the better investment. The analysis looks at factors like institutional ownership, profitability, earnings, valuation, risk, dividends, and analyst recommendations to contrast the two firms.

Why it matters

As small-cap biotech stocks, Prime Medicine and Athira Pharma represent potentially high-growth investment opportunities, but also carry more risk than larger, more established pharmaceutical companies. This analysis aims to help investors understand the relative strengths and weaknesses of each firm to make a more informed decision.

The details

The analysis finds that Prime Medicine has stronger institutional ownership at 70.4% compared to 57.1% for Athira Pharma. Prime Medicine also has a higher percentage of insider ownership at 22.7% versus 19.8% for Athira. On profitability metrics, Prime Medicine outperforms Athira Pharma. However, Athira Pharma is seen as having more potential upside, with analysts giving it a consensus target price 77.94% above its current trading level, compared to less upside projected for Prime Medicine.

  • The analysis was published on February 27, 2026.

The players

Prime Medicine

A biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address a wide spectrum of diseases.

Athira Pharma

A late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegradation, with a lead product candidate for Alzheimer's disease.

David Liu

The co-founder of Prime Medicine and a world-renowned leader in the field of gene editing.

Got photos? Submit your photos here. ›

What they’re saying

“We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies.”

— David Liu, Co-founder, Prime Medicine (transcriptdaily.com)

What’s next

Analysts will continue to monitor the progress and performance of both Prime Medicine and Athira Pharma as they advance their respective drug candidates and technologies.

The takeaway

This analysis highlights the potential of small-cap biotech firms like Prime Medicine and Athira Pharma to deliver outsized returns, but also the heightened risks involved. Investors will need to carefully weigh the relative strengths and weaknesses of each company to determine the best fit for their portfolio.